News for Healthier Living

New Therapeutic Target Expands Options for Multiple Myeloma

In a Phase I clinical trial, the investigational bispecific antibody cevostamab reduced cancer in more than 40% of patients with multiple myeloma.

July 22, 2026


August 1 2026

July 31 2026

July 30 2026

July 29 2026

July 28 2026

July 27 2026

July 26 2026

July 25 2026

July 24 2026

July 23 2026

July 22 2026

July 21 2026

July 20 2026